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Abstract  
Antithyroid drugs (ATDs) induced agranulocytosis is a rare but life threatening condition. We report a 29 years Filipino female diagnosed as having 
hyperthyroidism with normal base line blood counts, liver and renal profile. She was started on maximum 60mg (20mg TID) oral dose of 
carbimazole since one month by her treating physician. Exactly after one month of treatment she presented to emergency room (ER) with fever, 
sore throat and generalized weakness for several days. 
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Thyrotoxicosis is a common (2% prevalence), endocrine disorder 
among the females of reproductive age. The first line drugs used for 
its treatment are carbimazole and propylthiouracil, where 
carbimazole is the commonest used medication since 1991 [1]. 
ATDs known as thiomides, containing sulfhydral group and coupled 
with thiourea component as Propylthiouracil (6-propyl-2-thiouracil) 
and methimazole (1-methyl-mercaptimidazole) are the most 
common drugs used in United States. Methimazole is used in Asia 
and Europe including Great Britain usually for 18 months. These 
agents are actively concentrated against molar concentration 
gradient. They act by inhibiting the thyroid peroxidase enzyme 
decreasing iodization, coupling of iodide and tyrosine aminoacids 
present at the thyroglobulin molecule consequently decreasing 
production of thyroxin and tri-iodothyronine [2]. Being main stay of 
treatment antithyroid drugs however is recognized cause of 
hematopoeitic damage including agranulocytosis which is rare (0.3-
0.6%) but still a life threatening complication with a very high 
mortality (21.5%). High doses of ATDs are reported associated with 
increased incidence of agranulocytosis [3]. We present a patient 
who developed agranaulocytosis at one month of treatment on 
maximum dose of tablet carbimazole 20mg PO TID. She presented 
as having fever, sore throat and generalized weakness since 3 days 
and visited emergency room (ER) on three consecutive days. 
Temperatures recorded were 37.3c on first visit, 37c on 2nd visit 
and, 38.5c during 3rd visit respectively with low white blood count 
done consistent with agranulocytosis.  
  
  
Patient and observation 
 
29 years of old married Filipino female working as baby care 
presented on 25-02-2015 to medical outpatient department 
(OPD), with progressive swelling in front of her neck and heat 
intolerance since few months with irregular cycles. She is married 
since 3 years living with her husband but no history of conception. 
She had no past history of relevance. She was diagnosed on 19-3-
2015 in medical OPD as having severe hyperthyroidism based on 
her thyroid functions reports. Her thyroid hormone assay at the time 
of diagnosis was Thyroid stimulating hormone (TSH) = 0.0005Miu/L, 
free thyroxine (FT4)=73.6pmol/L and free tri-iodothyroxine (FT3) = 
46.08 pmol/L respectively. Her base line complete blood counts on 
19-03-2015 were, WBC = 8.0X10^6/micL, Neutrophils = 52%, 
Lymphocytes=41%, Monocytes=0%, Basophils = 2%, Eosinophils = 
1%, Red blood cells = 4.6x10^6/micL, Hemoglobin = 14gm/dL, 
Platelets = 284x10^3/micL, random blood glucose = 143mg/dL, 
renal and liver profile being normal, pregnancy test negative, Chest 
x-ray and ECG being unremarkable. Her blood pressure = 117/78 
mmHg, Heart rate = 90/min, Respiratory rate =18/min, and oxygen 
saturation (O2 SAT %) at room air were 99% respectively. She was 
afebrile and her booking weight was 57kgs. She was started on oral 
carbimazole (neomercazole) 20mg PO TID for one month along with 
Tab. Inderal 10mg PO TID with a one month supply of medications. 
Her next appointment was fixed after one month by the treating 
physician and there was no documentation on the possible drug 
related adverse effects.  
  
On 31-03-2015 she first time came to hospital emergency room 
(ER) complaining having generalized prostration and fever, her vitals 
were Blood Pressure (BP) = 110/70mmHg, heart rate (HR)=88/min, 
respiratory rate (RR) = 19/min, oxygen saturation (O2Sa) t=97% at 
room air, Temperature = 37.3c. She was reassured by the ER 
physician and discharged with Tab. paracetamol 1gm PO TID PRN. 
She was not asked about current medications and she did not 
disclose either. Before coming to ER she had taken 2 tablets (1gm) 
of paracetamol including her routine dose of carbimazole and 
Inderal 10 mg, and continued taking antithyroid medications. During 
her 2nd visit to the ER on 12-04-201, with the same complaints, 
her vitals were unremarkable and her temperature was normal = 
37c, because even this time she took as usual paracetamol and her 
dose of carbimazole including 10 mg inderal tablet before visiting 
the ER. She was reassured by the attending ER physician and 
discharged again; no laboratory work up was advised. On 16-04-
2015 during her 3rd visit to ER, She was referred to me as back-up 
on call physician by the ER physician for having unexplained low 
blood counts fever 38.5c, sore throat, prostration, BP = 
110/70mmHg, Heart rate = 112/min regular, Respiratory rate = 
20/min, O2Sat = 99% at room air, weight = 57 KG, and has a rash 
like face as noted by the ER physician.  
  
This young female Filipino (Muslim) was sitting on the edge of the 
bed covering her head, neck and upper torso with her hijab. Visible 
part of her face was blushed red manifesting hyperdynamic 
circulation but there was no specific skin rash otherwise. While 
asking her current medications on repeated questions about 
antibiotics or other drugs, at last only then she disclosed that she is 
taking treatment for her thyroid in the form of carbimazole, the 
dose of which she had taken even today just before coming to the 
ER. In addition when she was asked previously you were not having 
temperature when examined in ER she disclosed that usually before 
coming to the ER during her earlier visits she used to take 2 tablets 
of paracetamol. On removing the hijab, an obvious diffuse goiter 
was visible (Figure 1), rest of her systemic examination was 
unremarkable, heart rate = 112 and regular. In the light of history 
of her current antithyroid medications and low white blood counts 
WBC = 1.11X10^3/micL, Neutrophil = 11% , Lymphocytes = 78%, 
Hemoglobin = 13.4gm/dL, red blood cells (RBC) = 4.3X10^6/micL, 
Basophils = 1%, Monocytes = 0%, Eosinophils = 10%, Platelets = 
279x10^3/micL random blood glucose =143mg/dL, a diagnosis of 
ATD induced agranulocytosis was made. Her ATDs were 
discontinued and was admitted to medical HDU (high demand unit) 
under reverse isolation. After sending her septic workup, was 
started on injection Meropenem 1gm iv q8 hrs, ictaconazole 100mg 
PO OD, Tab. paracetamol 1gm po q8hrs prn, 5%DW/N.saline IV 
50ml/hr. Inderal 10mg PO TID was continued, Granulocyte colony 
stimulating factor (GCSF) as filgrastim, in a dose of 300micrograms 
SC OD was requested, which was difficult to arrange. Her complete 
blood counts from baseline to day of discharge are shown in Table 
1. On 2nd day of admission 17-4-2015 she had highest 
temperature 40c, her BP = 90/60mmHg, heart rate = 122/min, 
Respiratory rate=22/min, 02 SAT=100% at room air, she vomited 
twice and had one loose motion. Her WBC reported= 
3.25x10^6/micL, Neutrophils = 1%, Lymphocytes = 93%, 
Monocytes = 2%, Basophils = 0%, Eosinophls = 9%, Patelets = 
224x10^3/micL, RBC= 4.5X10^5/micL. Being skeptical of this 
complete blood count report, still she received first dose 300 mcg 
SC of GCSF in the afternoon. Same antibiotics were continued, 
Inderal was discontinued in regular doses in the anticipation of 
septicemia or septicemia shock, as her blood pressure was on the 
lower side with hyperpyrexia.  
  
Day 3rd 18-4-2015, WBC = 1.07x10^6/micL, Neutrophil count = 
1%, Lymphocytes = 91%, Mnocytes = 5%, Eosinophils = 4%, 
Basophils = 0%, Platelets = 237X10^3/micL, HB = 13.2, RBC = 4.3, 
BP = 100/5 8 mmHg, HR= 110/min, RR= 20/min, O2SAT = 99% at 
room air, Temp = 38.5c, liver function tests (LFTs) and renal 
function tests (RFTs) were normal, bowels and urinary habits 
normal and no more loose motions and vomiting. 4th day 19-4-
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2015, She was still febrile, Temp = 38c and WBC = 
2.02x10^6/micL, neutrophils = 1%, Lymphocytes = 94%, 
monocytes = 4%, Basophils = 0%, Eosinophils = 1%, RBCs and 
platelets being normal. Keeping in view the possibility of 
pseudomonas aeroginosa which is a common pathogen in 
agranulocytosis, and not strongly covered by meropenem, antibiotic 
treatment was changed to injection ceftazidime 1gm IV TID, while 
rest of the management continued as before. Urine bacterial culture 
reported negative. Thyroid functions reported, TSH=0.0006mIU/L, 
FT4=26.21pmol/L, FT3= 9.63Ppmol/L respectively, this was after 
about one month of treatment with carbimazole 20mg Po TID. Day 
5th 20-4-2015,the patient was feeling better and her BP 
110/75mmHg, HR = 90/min, RR=19/min, O2SAT = 99% at room 
air, Temp=37.4c, WBC= 0.84x10^6/micL, Neutrophil = 1, 
Lymphocyte = 95%, Mononcytes = 5%, Basophils = 1%, 
Eosinophils = 7%, she was feeling warm, she was still very 
particular with her hijab, she was asked to remove the upper torso 
covers and use light weight hijab. Throat swab culture reported 
klebsiella pneumonia sensitive to meropenem and ceftazidime, 
ceftriaxone. Same antibiotic was continued and her Inderal was 
restored 10mg PO TID, because now her BP was acceptable = 
110/70 mmHg. Day 6th 21-4-2015, She was feeling much more 
better no more fever, eating well and asking to be discharged, 
having BP = 115/70mmHg, HR=100/min, RR=19/min, O2 SAT = 
99%, Temp = 37c. Her stool and blood culture reported negative. 
Her WBC = 0.54x10^6/micL, Neutrophil = 1%, Lymphocytes = 
92%, Monocytes = 7%, Eosinophils = 4%, Basophils = 0%. 
Granulocyte colony stimulating factor (GCSF) filgrastim was not 
available. An external hematology consultation was done at this 
stage. Day 7th 22-4-2015, she was feeling warm but having normal 
temperature round the clock, BP = 115/75mmHg, HR=104/min 
regular, RR = 19/min, O2 SAT = 99%. WBC = 0.65x10^6/micL, 
Neutrophils = 1%, Lymphocytes = 92%, Methicillin resistance 
Staphylococcus aureus (MRSA) screening reported negative. At this 
stage control of her thyroxine hormone related effects was 
considered and her treatment was revised with addition of 5% 
Lugol's iodine solution 2 drops PO TID which unfortunately was not 
available, her dose of Inderal was increased to 20mg PO TID, and 
she was started on injection dexamethasone 4mg IV q8H, while 
empirical antibiotic inj. ceftazidime 1gm IV was continued to cover 
pseudomonas aeroginosa the commonest organism in 
agranulocytosis. She received 2nd dose of GCSF 300mcg arranged 
from other hospital pharmacy. Hematologist advised to continue the 
same treatment comprised of corticosteroids, GCSF along with 
antibiotics, but advised bone marrow biopsy as well. Day 8th 23-4-
2015, same line of management was continued without any 
change, and bone marrow biopsy was deferred till 4 weeks. She 
remained stable and afebrile, insisting for discharge, BP = 
115/75mmH, HR=84/min, RR = 19/min, O2SAT = 99% at room air, 
WBC = 0.75x10^6/micL, Neutrophil = 1%, Lymphocytes = 92%, 
Monocytes = 10%, Basophils = 0%, Eosinophils = 3%, she received 
3rd and the final dose of 300mcg SC of GCSF, as it was no more 
available.  
  
Day 9th 24-4-2015, she was asymptomatic and stable vitals, 
BP115/75mmHg, HR = 84/min, RR = 18/min, O2SAT = 99%, 
afebrile. Her WBC = 0.67x10^6/micL, Neutrophil = 1%, 
Lymphocyte = 88%, Monocytes = 10%, Basop-hils = 0%, 
Eosinophils = 1%, normal range platelets and RBCs. Day 10th 25-4-
2015, She was asymptomatic, and her WBC=0.59x10^6/micL, 
Neutrophil = 4%, Lymphocytes = 85%, Monocytes = 11%, 
Eosinophils = 0%, Basophils = 0%. Today first time complete blood 
counts showed beginning of neutrophil count rising with normal 
RBCs and platelets. Her heart rate was in normal range. Day 11th 
26-4-2015 & day 12th 27-4-2015, her full blood counts were WBC 
= 0.77x10^6/micL, Neutrophil = 28%, Lymphocytes = 56%, 
Monocytes = 14%,Eosinophils = 1%,Basophils = 1% and WBC = 
1.73x10^6/micL, Neutrophil = 38%, Lymphocytes = 45%, 
Monocytes = 15%, Basophils = 2%, Eosinophils = 0% respectively. 
As she had only two options for radical treatment: either surgery or 
radioactive iodine. A surgical consultation was done. She refused 
both the options despite being educated about the adverse effects 
of antithyroid medications and different available treatment options. 
Day13th 28-4-2015, she remained asymptomatic and was having 
normal vital signs. Her blood counts reported, 
WBC=2.16x10^6/micL, Neutrophils = 64%, Lymphocytes = 23%, 
Monocytes = 10%, Eosinophils = 1%, Basophils = 2%, Platelets 
and RBCs being in normal range. She was discharged on 
Ciprofloxacin 500mg PO bid for 5days, oral Prednisolone in tapering 
dose, tablet Inderal 30mg PO TID, tablet Omeprazole 20mg PO OD 
and was referred to the endocrinologist in an acute care hospital for 





Hyperthyroidism is a common endocrine condition more common in 
females in their reproductive years and main stay of treatment has 
been antithyroid drugs (ATD) since 1941[4]. Surgery and radio-
iodine were the other options. Carbimazole and thiouracil are the 
commonest antithyroid drugs used, and both could equally cause 
agranulocytosis or pancytopenia. Whereas hyperthyroidism or 
thyrotoxicosis is mostly a benign condition provided diagnosed 
early, its treatment with antithyroid drugs could cost the life of the 
patient causing fatal complications like agranulocytosis (0.3-0.6%) 
or pancytopenia. Factors indicating bad prognosis in ATDs induced 
hematopoietic damage are: age >65 years, pancytopenia, co-
existing liver and renal insufficiency. Patients may not have any 
symptoms or vague complaints and early clinical diagnosis become 
difficult under these circumstances .It is therefore mandatory to ask 
complete blood counts and liver functions at specific time i.e at 2 
weeks of ATD treatment to guard against ATDs induced 
agranulocytosis in asymptomatic patients [4,5]. Diagnosis of 
agranulocytosis is made when patients show a granulocyte count 
below 5>00 /ul after ATD therapy [5]. ATD induced pancytopenia is 
defined when in addition to agranulocytosis patients show 
hemoglobin less than 11gm/dl and a platelet count less than 
100x10/liter. Recovery from ATD induced agranulocytosis or 
pancytopenia is defined as improvement in granulocyte counts to 
500/ul or more. Hematopoetic damage could be present without 
patients manifesting any symptoms, therefore asking a full blood 
count at every 2 weeks is recommended [6]. Patients' needs to be 
educated by the clinicians with full documentation about signs and 
symptoms of ATD induced side effects like fever, sore throat, 
prostration,skin rash etc, where they should be asked to stop taking 
medications and seek medical advice. Who will develop 
hematopoetic damage is not pre-determined despite of various 
postulated underlying mechanisms mentioned below: a)Antibodies 
against antithyroid drug bound to the wall of the granulocyte cause 
accelerated destruction of the granulocytes; b)Antibodies may 
target drug/metabolite complex adsorbed to the neutrophil in the 
presence of a plasma /complement component; c)The drug may 
trigger the production of autoantibodies targeting granulocytes or 
drug metabolites may directly target neutrophils when used in 
higher doses; d)Interaction of a granulocyte antigen and drug may 
induce the production of antibodies; e)Besides above mechanisms, 
idiosyncratic drug induced agranulocytosis (which is independent of 
the dose) is a severe selective depression of myelopoeisis. It is due 
to an unpredictable adverse reaction to a wide variety of drugs in 
hypersensitive individuals-occurring in first 1-2 months of taking 
antithyroid drug. In the end it could just be labelled as a random 
bad luck [7].  
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ATD induced agranulocytosis when present, is 10 times more 
common than pancytopenia. Mortality in agranulocytosis is high up 
to 21.5% and much higher in pancytopenia. Overwhelming 
infections are the cause of life threatening septicemia and 
septicemic shock. ATD induced hematopoetic damage usually is 
anticipated after 2 weeks to 14 weeks. Fever and sore throat were 
the most common presenting complaints besides prostration. 
Besides complete blood counts liver function also needs to be 
monitored simultaneously [8]. Renal and liver functions remained 
normal in our patient. Patients are usually treated conservatively 
with supportive measures after stopping the offending drug. 
Patients are kept in reverse isolation and after sending the septic lab 
work up ,are started emperical broadspectrum antibiotics for the 
most commonly expected bacteria like streptococcus pneumoniae, 
klebsiella pneumoniae, Pseudomonas aeruginosa etc, iv fluids, 
antifungal medications. Use of GCSF since 1991, has improved the 
prognosis by reducing the recovery time of the granulocytes in large 
majority of the patients, but despite of its use ,mortality still remains 
high up to 5% [9]. GCSF is less effective in ATDs induced 
pancytopenic patients, but still is more effective here compared to 
bone marrow failure induced by cancer therapy or radiations. Bone 
marrow biopsy is better deferred till four weeks; it takes about 5 
days to 2 weeks for the neutrophil recovery. GCSF better be 
continued till desired response. Simultaneous addition of 
corticosteroids like dexamethasone 4 mg iv q8h or 
methylprednisolone 1gm IV q8h has augumenting anti-inflamtory 
effect on recovery of the hematopoietic stem cells [10]. The most 
common and better tolerated daily dose of Carbimazole used is in 
range of 15-45mg given in three divided doses. Supply of ATDs is 
selectively given according to the reliable intelligence and 
knowledge of the patient. It is safe to supply 2 weeks treatment to 
those less educated as our patient; she went on taking ATD despite 
of being sick. Maximum or higher doses at the start better be 
avoided. At 4 weeks the dosage could be safely revised up or down 
according to the response [11]. Patients' needs to be educated by 
the clinicians about signs and symptoms of ATD induced side effects 
with full documentation. None of the two were done in this case as 
revealed in the medical records. Adverse effects include fever, sore 
throat, prostration, skin rashes, liver derangement where patients 
are asked to stop taking medications and seek immediate medical 
advice. All patients have not the same knowledge and 
understanding about the adverse effects of ATDs. The subject 
patient was started on the maximum dose of ATDs from the start 
and at the top of that was given supply for the whole one month 
which she continued taking even after being sick. It is therefore safe 
to prescribe 2 weeks supply of ATDs in the start, especially to less 
educated patients as ours. Bone marrow in cases of antithyroid 
induced hematopoetic depression is non-contributory at least 
initially, and better be deferred till 4 weeks. It is because, after 
stopping the offending drug (ATD), starting broad spectrum 
antibiotics and giving GCSF continuously with concomitant 
corticosteroids till neutrophilic response, has really improved the 
outcomes in large majority of patients. Despite of all these 
measures still there is 5% mortality rate reported, therefore 
prevention and early detection of antithyroid induced 





Severity of hyperthyroidism and doses of ATDs better be judged and 
decided based on symptoms and not on the figures (values) of the 
thyroid hormones. All patients have not the same knowledge and 
understanding about the adverse effects of ATDs. It is therefore 
safe to prescribe 2 weeks supply of ATDs in the start, especially to 
less educated patients as ours. The initiation of carbimazole in 
average dose range of 15-45 mg in divided doses and supply of 2 
weeks medication is a safe choice .After 4 weeks antithyroid 
treatment, the dosage could be revised according to the response. 
Patients’ needs to be educated by the clinicians about signs and 
symptoms of ATD induced side effects with full documentation. 
Conducting routine complete blood counts at 2 weeks on wards is 
beneficial in alerting the clinicians to the possibility of ATD induced 
agranulocytosis, it may detect those cases having no symptoms but 
still having low blood counts predicting underlying pre-disposition to 
hematopoetic damage. History of current medications needs to be 
given due importance. This patient was diagnosed having ATD 
induced agranulocytosis during her 3rd ER visit, by virtue of taking 
history of current medications coupled with her low WBC and 
neutrophil counts. Availability of Broad spectrum antibiotics has 
improved the prognosis and outcomes of ATD induced 
agranulocytosis. Further improvement in prognosis is attributed to 
the use of GCSF by decreasing the duration of neutrophil recovery in 
ATD induced agranulocytosis. But despite of GCSF utility, mortality 
remains high (5%), especially in pancytopenic patients, therefore its 
prevention and early detection has prognostic value. Bone marrow 
is non- contributory in ATDs induced hematopoetic injury at least 
initially and better be deferred until 4 weeks. It is because,after 
stopping the offending drug (ATD), starting broad spectrum 
antibiotics and giving GCSF continuously with concomitant 
corticosteroids till neutrophilic response, has really improved the 
outcomes in large majority of patients.On the contrary bone marrow 
suppression induced by chemotherapy or radiations has guarded 
prognosis and takes longer time to respond if at all. It is here when 
an early bone marrow biopsy may help to tailor treatment and 
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Table and figure 
 
Table 1: Complete blood counts baseline and admission to the day 
of discharge  
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Table 1: complete blood counts baseline and admission to the day of discharge 



















8 4.6 284 52 41 0 2 1 




1.11 4.3 279 11 78 0 1 10 
Day 2 
17-04-2015* 
3.25 4.5 224 1 93 2 0 9 
Day 3 
18-04-2015 
1.07 4.3 237 1 91 5 0 4 
Day 4 
19-04-2015 
2.02 4.2 300 1 94 4 0 1 
Day 5 
120-04-2015 
0.84 4.5 370 1 95 5 1 7 
Day 6 
21-04-2015 
0.54 4 265 1 92 7 0 4 
Day 7** 
22-04-2015 
0.65 5 400 1 92 8 0 4 
Day 8*** 
23-04-2015 
0.75 4.7 288 1 92 10 0 3 
Day 9 
24-04-2015 
0.67 4.7 275 1 88 10 0 1 
Day 10 
25-04-2015 
0.59 5.2 255 4 85 11 0 0 
Day 11 
26-04-2015 
0.77 4.7 277 28 56 14 1 1 
Day 12 
27-04-2015 




2.16 4.7 300 64 23 10 2 1 
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Figure 1: Goitre (hyperthyroidism)  
 
 
 
 
